|
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response |
Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD. Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. Value in Health 2012; 15(6): 876-886 Indexing Status Subject indexing assigned by NLM MeSH Adult; Antiviral Agents /administration & Comparative Effectiveness Research; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hepacivirus /drug effects /genetics; Hepatitis C, Chronic /drug therapy /virology; Humans; Interferon-alpha /administration & Male; Middle Aged; Models, Theoretical; Polyethylene Glycols /economics /therapeutic use; Recombinant Proteins /economics /therapeutic use; Ribavirin /administration & Treatment Outcome; Young Adult; dosage /economics; dosage /economics; dosage /economics /genetics /therapeutic use AccessionNumber 22012037251 Date bibliographic record published 29/01/2013 |
|
|
|